Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties

BioArctic AB

20/05/2026 06:11

Overview

Sweden biopharma firm's Q1 revenue fell sharply yr/yr despite higher Leqembi royalties and milestone

Q1 adjusted EPS declined yr/yr as prior-year results included larger milestone payments

Company received SEK 20 mln milestone payment as Leqembi global sales exceeded EUR 500 mln

Outlook

Eisai forecasts Leqembi sales of JPY 143.5 bln for fiscal yr 2026, up 63% y/y

FDA extends review period for Leqembi Iqlik sBLA; new PDUFA date is Aug 24, 2026

Result Drivers

LEQEMBI ROYALTIES - Higher royalty income from Leqembi contributed to Q1 results

MILESTONE PAYMENT - SEK 20 mln milestone payment received as Leqembi sales exceeded EUR 500 mln

Company press release: ID:nWkr3S6VxW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 437.60 mln
Q1 Adjusted EPS
SEK 2.40
Q1 Net Income
SEK 212.40 mln
Q1 Adjusted Free Cash Flow
-SEK 166 mln
Q1 Operating profit
SEK 210.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BioArctic AB is SEK346.00, about 9.1% above its May 19 closing price of SEK317.00

The stock recently traded at 70 times the next 12-month earnings vs. a P/E of 103 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)